Provided is a use of a prodrug composition containing a naphthoquinone-based compound of Formula 1 for the manufacture of a medicament for treatment or prevention of metabolic syndrome diseases. ##STR00001## wherein R.sub.1 to R.sub.10, X, m and n are as defined in the specification.